Cyclopharm Limited ( (AU:CYC) ) has provided an update.
Cyclopharm Limited has announced that its Annual General Meeting will be held on May 13, 2025, with director nominations closing on March 24, 2025. This announcement is part of the company’s ongoing governance and operational updates, which could impact its strategic direction and stakeholder engagement.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community. Its mission is to enhance patient care outcomes through its core product, Technegas®, which is used in functional lung ventilation imaging. Technegas® is a fine dispersion of radioactive-labelled carbon for evaluating lung ventilation, historically used for diagnosing pulmonary embolism and now also applied in conditions like COPD, asthma, and pulmonary hypertension.
YTD Price Performance: -11.67%
Average Trading Volume: 141,582
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$155.6M
See more insights into CYC stock on TipRanks’ Stock Analysis page.